TY - JOUR
T1 - Economic impact of chronic prostatitis
AU - Duloy, Anna M.S.
AU - Calhoun, Elizabeth A.
AU - Clemens, J. Quentin
N1 - Funding Information:
12.•• McNaughton-Collins M, Joyce GF, Wise M, Pontari MA: Prostatitis. In Urologic Diseases in America. Edited by Litwin MS, Saigal CS. NIH publication no. 07-5512. US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Washington, DC: US Government Publishing Office; 2007:11–39.
PY - 2007/7
Y1 - 2007/7
N2 - There are four types of prostatitis, including type I (acute bacterial prostatitis), type II (chronic bacterial prostatitis), type 111 (chronic prostatitis/chronic pelvic pain syndrome, or CP/CPPS), and type IV (asymptomatic inflammatory prostatitis). These prostatitis conditions account for approximately 2 million office visits each year to primary care physicians and urologists. The annual cost to treat prostatitis is approximately $84 million. Compared with control subjects, men with prostatitis incur significantly greater costs, predominantly due to increased outpatient visits and pharmacy expenses. CP/CPPS is the most common type of prostatitis. The condition is characterized by chronic, idiopathic pelviperineal pain. Due to the lack of effective treatments for CP/CPPS, the per-person costs associated with the condition are substantial and are similar to those reported for peripheral neuropathy, low back pain, fibromyalgia, and rheumatoid arthritis. Costs appear to be higher in men with more severe symptoms. Indirect costs (eg, work and productivity loss) are incurred by many patients with CP/CPPS. Identification of effective treatments for CP/CPPS would be expected to substantially reduce the costs associated with the condition.
AB - There are four types of prostatitis, including type I (acute bacterial prostatitis), type II (chronic bacterial prostatitis), type 111 (chronic prostatitis/chronic pelvic pain syndrome, or CP/CPPS), and type IV (asymptomatic inflammatory prostatitis). These prostatitis conditions account for approximately 2 million office visits each year to primary care physicians and urologists. The annual cost to treat prostatitis is approximately $84 million. Compared with control subjects, men with prostatitis incur significantly greater costs, predominantly due to increased outpatient visits and pharmacy expenses. CP/CPPS is the most common type of prostatitis. The condition is characterized by chronic, idiopathic pelviperineal pain. Due to the lack of effective treatments for CP/CPPS, the per-person costs associated with the condition are substantial and are similar to those reported for peripheral neuropathy, low back pain, fibromyalgia, and rheumatoid arthritis. Costs appear to be higher in men with more severe symptoms. Indirect costs (eg, work and productivity loss) are incurred by many patients with CP/CPPS. Identification of effective treatments for CP/CPPS would be expected to substantially reduce the costs associated with the condition.
UR - http://www.scopus.com/inward/record.url?scp=34547401595&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34547401595&partnerID=8YFLogxK
U2 - 10.1007/s11934-007-0081-x
DO - 10.1007/s11934-007-0081-x
M3 - Review article
C2 - 18519019
AN - SCOPUS:34547401595
VL - 8
SP - 336
EP - 339
JO - Current Urology Reports
JF - Current Urology Reports
SN - 1527-2737
IS - 4
ER -